NCT00250432View on ClinicalTrials.gov

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

204

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

March 31, 2008

Conditions

Invasive Candidiasis

Interventions

DRUG

caspofungin acetate

Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. Duration of Treatment - 14-90 days.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00250432 - A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED) | Biotech Hunter | Biotech Hunter